A biotech company can have a strong platform, credible data, and a real clinical need in front of it, then still struggle to gain traction because the message lands nowhere. The research team talks in mechanisms and endpoints. The founder talks in mission. The investor deck talks in milestones. The hiring page talks in culture. None of those stories are wrong. They're just disconnected. That gap causes more damage in biotechnology than it does in most industries. A software company can often revise a landing page and move on. A biotech company is operating under scrutiny from clinicians, investors, regulators,
Continue reading